Cargando…
How government health insurance coverage of novel anti-cancer medicines benefited patients in China – a retrospective analysis of hospital clinical data
BACKGROUND: China started to cover novel medicines for the treatment of major cancers, such as trastuzumab for breast cancer by the government health insurance programs since 2016. Limited data have been published on the use of cancer medications and little is known about how government health insur...
Autores principales: | Diao, Yifan, Lin, Mengbo, Xu, Kai, Huang, Ji, Wu, Xiongwei, Li, Mingshuang, Sun, Jing, Li, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380313/ https://www.ncbi.nlm.nih.gov/pubmed/34419013 http://dx.doi.org/10.1186/s12913-021-06840-3 |
Ejemplares similares
-
Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design
por: Diao, Yifan, et al.
Publicado: (2022) -
The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China—In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data
por: Li, Mingshuang, et al.
Publicado: (2021) -
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study
por: Diao, Yifan, et al.
Publicado: (2019) -
China’s Insurance Regulatory Reform, Corporate Governance Behavior and Insurers’ Governance Effectiveness
por: Li, Huicong, et al.
Publicado: (2017) -
Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective
por: Diao, Yifan, et al.
Publicado: (2019)